Instituto de Investigación Hospital 12 de Octubre

Instituto de Investigación Hospital 12 de Octubre is the research institute linked to Hospital 12 de Octubre in Madrid. In the book’s publication framework, it appears not as an abstract affiliation but as part of the institutional setting through which hepatitis C is examined across hepatology, nephrology, dialysis, transplantation, and HIV-associated renal disease. Its presence connects clinical investigation with the wider international effort to define, diagnose, treat, and prevent HCV-related disease.

Identity and Institutional Setting

Instituto de Investigación Hospital 12 de Octubre is identified with Hospital 12 de Octubre and Universidad Complutense de Madrid in Madrid, Spain. The institute’s address is given as ES-28001 Madrid, and its name appears in the publication’s front matter alongside the affiliation of Jose M. Morales. Morales later identifies the hospital and the institute as sources of continuing stimulus for the project, placing the organization within the practical institutional environment that supported the volume’s production.

The institute’s identity is therefore tied to both hospital medicine and organized research. The evidence presents it as a Madrid-based center participating in work that treats HCV as a systemic disease rather than solely a liver disorder. That framework encompasses autoimmune, dermatological, and renal manifestations and requires collaboration among specialists concerned with chronic kidney disease, hemodialysis, and transplantation.

Role in the Book’s Scholarly Project

The institute is acknowledged as part of the support structure behind the volume Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Morales describes the book as a review of important developments in HCV infection and nephrology, dialysis, and transplantation, including renal disease and dialysis problems in the general population, complications in renal transplant patients, and renal complications associated with HCV in patients with HIV infection. The institute thus stands behind a project whose scope moves repeatedly between laboratory definition, clinical diagnosis, treatment decisions, and long-term transplant outcomes.

That scope is reflected in the book’s technical distinctions. Chronic active HCV infection is established through both anti-HCV positivity and detectable HCV RNA, while liver injury is assessed through biopsy or noninvasive methods such as FibroScan. Extrahepatic disease is also central: HCV is described as the major cause of mixed cryoglobulinemia, a systemic vasculitis that may include renal disease, and HCV-associated cryoglobulinemic membranoproliferative glomerulonephritis is treated as a clinically consequential renal manifestation. The institute’s association with this work places it within a research culture attentive to the difference between exposure, active infection, organ injury, and clinical syndrome.

Research Domains and Clinical Questions

The research agenda represented through the institute extends from population health to specialized renal pathology. The book describes a worldwide burden of more than 150 million, or approximately 170 million, HCV-infected people and emphasizes that infection remains a major health problem even after advances in diagnosis, prevention, and therapy. It also follows the historical movement from post-transfusion and nosocomial hepatitis toward molecular diagnosis, genotype classification, direct-acting antiviral drugs, and more precise treatment selection.

Within nephrology, the institute’s associated subject matter includes screening kidney-transplant candidates, evaluating concealed liver fibrosis, treating HCV in chronic kidney disease, and interpreting renal allograft injury. Up to 25% of candidates with active HCV infection may have advanced fibrosis on liver biopsy despite well-compensated liver disease, which makes systematic screening clinically important. The same body of evidence describes HCV-infected renal allograft recipients as vulnerable to immune complex-mediated glomerulonephritis, including de novo membranoproliferative glomerulonephritis and, in some cases, membranous glomerulonephritis.

The institute is also situated within the book’s concern for dialysis safety and infection control. Hemodialysis patients were recognized as a high-risk group after HCV testing became available, first because of the historical use of transfusions and later because evidence pointed toward nosocomial transmission within dialysis units. The KDIGO workgroup found that dedicated dialysis machines were not recommended and that isolating HCV-infected patients was not an adequate substitute for strict infection-control procedures. These questions broaden the institute’s implied research role from treating individual disease to understanding how medical systems can generate, detect, and prevent transmission.

Institutional Networks and Significance

The institute’s importance in the book is relational. It is connected to Hospital 12 de Octubre, Universidad Complutense de Madrid, the editors and international authors, and the guideline-driven fields of nephrology and transplantation. Morales notes that many contributors were investigators involved with KDIGO and credits their work with advancing knowledge of HCV infection in chronic kidney disease. The institute is consequently presented as one node in a transnational network of hospitals, investigators, professional groups, and publishers rather than as an isolated local organization.

Its significance also lies in the way it helps join clinical evidence to institutional decision-making. The volume discusses treatment according to viral kinetics, the risks of interferon-based therapy in chronic kidney disease, the renal elimination of ribavirin, and the need to balance kidney disease, liver disease, treatment toxicity, and comorbidities. It also examines consequences after transplantation, including proteinuria, membranoproliferative glomerulonephritis, transplant glomerulopathy, and graft loss. Through these linked problems, Instituto de Investigación Hospital 12 de Octubre represents the kind of hospital research setting in which HCV is made legible as a disease crossing organs, specialties, and stages of care.

The organization’s final profile is therefore one of continuity and connection. It supports a Madrid hospital’s participation in a broad medical investigation, helps anchor the book’s Spanish institutional identity, and is associated with a research program that follows HCV from screening and molecular confirmation through antiviral therapy, dialysis infection control, renal pathology, and transplantation outcomes.